{
    "code": "60001206",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001206",
    "time": "2023-03-17 03:50:49",
    "許可證字號": "衛部菌疫輸字第001206號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/11\/15",
    "發證日期": "111\/11\/15",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000120604",
    "中文品名": "拓達維注射劑",
    "英文品名": "TRODELVY for Injection",
    "適應症": "適用於治療先前已接受兩次以上全身性治療無效(其中一次需為治療晚期疾病)之無法切除的局部晚期或轉移性的三陰性乳癌成年病人。",
    "劑型": "243凍晶注射劑",
    "包裝": "100支以下盒裝 180毫克玻璃小瓶裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "基因工程產品_新成分",
    "監視期限": "116\/11\/15",
    "主成分略述": "sacituzumab govitecan",
    "限制項目": "02輸　入 5G小兒\/少數嚴重疾病藥品認定",
    "申請商名稱": "620117L277  香港商吉立亞醫藥有限公司台灣分公司",
    "申請商地址": "臺北市信義區松仁路32號10樓之1、36號10樓之1",
    "主製造廠": [
        {
            "製造廠名稱": "FIT0479000  BSP PHARMACEUTICALS S.p.A",
            "製造廠廠址": "VIA APPIA KM 65,561, LATINA SCALO(LT), 04013, ITALY",
            "製造廠公司地址": "",
            "製造廠國別": "ITALY",
            "製程": "原料藥及成品製造廠"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FIE0060000  GILEAD SCIENCES IRELAND UC",
            "製造廠廠址": "IDA BUSINESS &amp; TECHNOLOGY PARK, CARRIGTOHILL COUNTY CORK, IRELAND",
            "製造廠公司地址": "",
            "製造廠國別": "IRELAND",
            "製程": "二級包裝廠"
        },
        {
            "製造廠名稱": "FKR0186000  Samsung Biologics Co. Ltd.",
            "製造廠廠址": "300 Songdo bio-daero, Yeonsu-gu, Incheon City, Korea 21987, Korea Republic",
            "製造廠公司地址": "",
            "製造廠國別": "KOREA",
            "製程": "中間體製造"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013010300",
            "成分名稱": "sacituzumab govitecan",
            "含量描述": "",
            "含量": "180.0000000000",
            "單位": "MG"
        }
    ]
}